Navigation Links
PICA Policyholders Approve ProAssurance Transaction
Date:3/31/2009

BIRMINGHAM, Ala. and NASHVILLE, Tenn., March 31 /PRNewswire-FirstCall/ -- ProAssurance Corporation (NYSE: PRA) announced today that the policyholders of the Podiatry Insurance Company of America (PICA) have overwhelmingly approved the sponsored demutualization that will bring PICA into ProAssurance as a standalone subsidiary. The transaction, which requires final regulatory approval in PICA's domiciliary state of Illinois, is expected to close early in the second quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081024/PROASSURANCELOGO)

Under the agreement, approved today in a special meeting of policyholders, a total of $120 million is being paid to current and certain former policyholders in accordance with the approved plan of demutualization. The plan of demutualization also provides a total of $15 million in premium credits to eligible renewing PICA policyholders beginning in 2010 and spread over three years.

Policyholders who are due to receive a cash payment have until the close of business on Friday, April 10, 2009 to furnish properly completed paperwork to PICA or its paying agent, BNYMellon Shareowner Services. Policyholders who do not furnish the proper paperwork will be subject to federally mandated tax withholding on the payments due to them. Policyholders with questions about their paperwork may call PICA at (800) 913-0153.

About ProAssurance

ProAssurance Corporation is the nation's fifth largest writer of medical professional liability insurance and is growing its legal professional liability business. ProAssurance is recognized as one of the top performing insurance companies in America by virtue of its inclusion in the Ward's 50 for the past two years.

About PICA

PICA is the nation's leading provider of professional liability to doctors of podiatric medicine, insuring approximately 9,800 podiatric physicians in 47 states and the District of Columbia. PICA insures other health care professionals and provides E&O insurance for a small, but growing, number of independent insurance agents through its subsidiary PACO. PICA wrote approximately $96 million in direct premium in 2008, has $284 million in total assets and has maintained an A. M. Best rating of "A-" (Excellent) for the past 13 years.

Caution Regarding Forward-Looking Statements

Statements in this news release that are not historical fact or that convey our view of future business, events or trends are specifically identified as forward-looking statements. Forward looking statements are based upon our estimates and anticipation of future events and highlight certain risks and uncertainties that could cause actual results to vary materially from our expected results. We expressly claim the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, for any forward-looking statement in this news release.

Forward-looking statements represent our outlook only as of the date of this news release. Except as required by law or regulation, we do not undertake and specifically decline any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Forward-looking statements are generally identified by words such as, but not limited to, "anticipate," "believe," "estimate," "expect," "hope," "hopeful," "intend," "may," "optimistic," "potential," "preliminary," "project," "should," "will," and other analogous expressions. When we address topics such as liquidity and capital requirements, return on equity, financial ratios, net income, premiums, losses and loss reserves, premium rates and retention of current business, competition and market conditions, the expansion of product lines, the development or acquisition of business in new geographical areas, the availability of acceptable reinsurance, actions by regulators and rating agencies, court actions, legislative actions, payment or performance of obligations under indebtedness, payment of dividends, and other similar matters, we are making forward looking statements.

The following important factors are among those that that could affect the actual outcome of future events:

  • general economic conditions, either nationally or in our market areas, that are different than anticipated;
  • regulatory, legislative and judicial actions or decisions could affect our business plans or operations;
  • the enactment or repeal of tort reforms;
  • formation of state-sponsored malpractice insurance entities that could remove some physicians from the private insurance market;
  • the impact of deflation or inflation;
  • changes in the interest rate environment;
  • the effect that changes in laws or government regulations affecting the U.S. economy or financial institutions, including the Emergency Economic Stabilization Act of 2008 and the American Recovery and Reinvestment Act of 2009, may have on the U.S. economy and our business;
  • performance of financial markets affecting the fair value of our investments or making it difficult to determine the value of our investments;
  • changes in accounting policies and practices that may be adopted by our regulatory agencies and the Financial Accounting Standards Board, or the Securities and Exchange Commission;
  • changes in laws or government regulations affecting medical professional liability insurance or the financial community;
  • the effects of changes in the health care delivery system;
  • uncertainties inherent in the estimate of loss and loss adjustment expense reserves and reinsurance and changes in the availability, cost, quality, or collectability of insurance/reinsurance;
  • the results of litigation, including pre-or-post-trial motions, trials and/or appeals we undertake;
  • bad faith litigation which may arise from our handling of any particular claim, including failure to settle;
  • loss of independent agents;
  • changes in our organization, compensation and benefit plans;
  • our ability to retain and recruit senior management;
  • our ability to purchase reinsurance and collect payments from our reinsurers;
  • increases in guaranty fund assessments;
  • our ability to achieve continued growth through expansion into other states or through acquisitions or business combinations;
  • changes to the ratings assigned by rating agencies to our insurance subsidiaries, individually or as a group; changes in competition among insurance providers and related pricing weaknesses in our markets; and
  • the expected benefits from completed and proposed acquisitions may not be achieved or may be delayed longer than expected due to business disruption, loss of customers and employees, increased operating costs or inability to achieve cost savings, and assumption of greater than expected liabilities, among other reasons.

Additional risk factors that may cause outcomes that differ from our expectations or projections are described in various documents we file with the Securities and Exchange Commission, such as our current reports on Form 8-K, and our regular reports on Forms 10-Q and 10-K, particularly in "Item 1A, Risk Factors."


'/>"/>
SOURCE ProAssurance Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MHA Insurance Company Offers Financial Incentive to Physician Policyholders Who Use Electronic Medical Records
2. New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders
3. The Hanover Ready to Serve Policyholders Impacted by Hurricane Dolly
4. Credit Relief Extended to State Fund Policyholders Impacted by Southern California Fires
5. FDA Approves First Anti-Psychotic for Kids
6. FDA Approves New Roche West Nile Virus Blood Screening Test
7. $52.5 Million Settlement Against Sepracor Inc. Approved
8. United Medicorp, Inc.s Shareholders Approve All Proposals
9. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
10. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
11. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... Cellairis is a worldwide mobile device and computer repair franchise that is known ... Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up for business ... customers. While customers do their shopping, Cellairis can accomplish a number of mobile device ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, ... safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP FOR ... easy to use and could be set up in a matter of minutes, or ...
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: